Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
VMD to ban some flukicides
Use of certain flukicides to be banned in milk-producing animals

The VMD have announced a ban on the use of certain flukicides in animals producing milk for human consumption. Speaking last week at the Animal Health Distributors Association conference, Paul Green, director of operations at the directorate said the decision had come from the European Commission (EC). The ban aims to "clarify and harmonise" the advice on using these types of products across the member states.

Mr Green said: "The advice confirms that products containing clorsulon, closantel, nitroxinil, triclabendazole and rafoxanide are not authorised for use in animals producing milk for human consumption, including during the dry period."

However, he added that products containing one of these compounds as their sole active substance will be subject to "specific directions", with regards to their use in heifers and ewes prior to the first calving or lambing. For example, clostanel can be given to pregnant cattle, but not during the second half of pregnancy, whereas triclabendazole cannot be used within the year prior to the first lambing or kidding in sheep and goats respectively.

No UK-authorised products contain rafoxanide, and clorsulon is currently only included in UK products in combination with a second active substance, meaning there are no special circumstances with either of these two substances.

According to the directorate, the decision by the EC comes after a "community interest referral", which is a change initiated by concerns regarding the protection of the EU's human and/or animal health. As a result of the decision there will be major changes to the labelling of affected products across the EU. Mr Green said that the marketing authorisation holders (MAHs) concerned were taking the "necessary steps" to introduce the new labelling. Products containing the new advice will start to become available "in about six months time".

More information and a complete list of the specific directions is available on the VMD's website.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.